NASDAQ$ABCL
AbCellera Biologics Inc. · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
AbCellera reported fourth quarter results, highlighting revenue and net loss figures.
AbCellera reported Q4 2024 revenue of $5.1 million and a net loss of $34.2 million. The company continues to advance its pipeline and invest in its capabilities.
- Revenue for Q4 2024 was $5.1 million, primarily from research fees.
- Operating expenses for Q4 2024 totaled $77.8 million, including investments in co-development and internal programs.
- Net loss for Q4 2024 was $34.2 million, or $(0.12) per share.
- Abdera advanced ABD-147 into a Phase 1 clinical trial.
Headline financials
Revenue & EPS history
AbCellera · Revenue · Quarterly
$5.1M
Revenue by segment
AbCellera · $6.6M total across 2 segments · Q3 2023
- Research Fees$6.41M-14.6%97.2%
- Licensing and Royalty$186K+20.8%2.8%
Forward guidance
AbCellera is on track to initiate Phase 1 clinical trials for ABCL635 and ABCL575 and start activities in its new clinical manufacturing facility in 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-0.4%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.2%
Avg return
30 days after
46%
11 / 24 earnings
Positive
+17.1%
Q2 2021
Best reaction
-13.9%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | -21.8% | -2.9% | |
| Q4 2025 | -1.5% | +18.6% | +1.6% | |
| Q3 2025 | -13.9% | -12.4% | -21.4% | |
| Q1 2025 | +1.0% | +2.0% | +21.4% | |
| Q4 2024 | -11.3% | -18.2% | -20.9% | |
| Q3 2024 | -0.4% | -1.1% | +6.2% | |
| Q2 2024 | -4.7% | -2.9% | -12.0% | |
| Q1 2024 | -6.6% | -6.8% | -8.0% | |
| Q4 2023 | -9.9% | -8.8% | -11.8% | |
| Q3 2023 | +14.1% | +6.8% | +17.2% | |
| Q2 2023 | -13.0% | -15.1% | -19.5% | |
| Q1 2023 | -9.1% | -14.1% | +3.0% | |
| Q4 2022 | -8.3% | -12.7% | -23.8% | |
| Q3 2022 | -1.7% | +13.1% | -7.2% | |
| Q2 2022 | +13.4% | +16.3% | -3.9% | |
| Q1 2022 | -12.0% | +11.2% | +29.1% | |
| Q4 2019 | +8.1% | +9.4% | +15.5% | |
| Q4 2021 | +8.1% | +9.4% | +15.5% | |
| Q3 2020 | -7.8% | -2.0% | -5.1% | |
| Q2 2018 | +16.3% | +10.3% | +25.0% | |
| Q2 2021 | +17.1% | +8.6% | +24.3% | |
| Q1 2018 | +0.1% | -5.2% | -24.1% | |
| Q1 2021 | +3.4% | +7.4% | -15.7% | |
| Q4 2018 | +7.8% | +24.1% | +21.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro